Liongho Chua

LiongHo Chua joined Clover Biopharmaceuticals as President of Greater China. Prior to joining Clover, Mr. Chua served as the Executive President and Chief Strategy Officer for AIM Vaccine. Before AIM Vaccine, he held the position of Country Manager for Sandoz China, a leader in generic and biosimilar pharmaceuticals, where he successfully implemented a market access strategy for its portfolio of products. Prior to Sandoz, he was the Vice President and General Manager, Asia Commercial Operations for Gilead Sciences, Inc. where he was instrumental in launching their Hepatitis C, Hepatitis B, and HIV antiviral drugs across Asia. Earlier in his career, Mr. Chua was the General Manager for Sanofi Pasteur China. He has also held roles with MSD (Merck), Philips Medical Systems, Baxter Healthcare in China and Fresenius AG in Singapore.

Mr. Chua is a registered pharmacist and holds a Bachelor of Science in Pharmacy from the National University of Singapore. Before starting his commercial career at Fresenius AG, Mr. Chua was a practicing clinical pharmacist.